Download Prof. Dr. Carsten Bokemeyer

Curriculum Vitae:
Prof. Dr. Carsten Bokemeyer
Present Ranks:
Director
Department of Oncology, Hematology, Bone Marrow
Transplantation with section Pneumology
Department of Medicine
University Hospital Hamburg-Eppendorf
Hamburg, Germany
Director University Cancer Center Hamburg
University Hospital Hamburg-Eppendorf
Hamburg, Germany
Education:
1989
1989
1989-1995
1995-2004
M. D. / University of Hannover Medical School, Hannover,
Germany
FMGEMS
Internal Medicine Internship / Residency
University of Hannover Medical School
Hannover, Germany
Faculty Member
Department of Internal Medicine
Division of Hematology / Oncology / Immunology / Rheumatology
University of Tuebingen Medical Center
Tuebingen, Germany
Academic Appointments:
1996
“Habilitation” (Postdoctoral lecturing qualification)
Department of Internal Medicine
Medical School Hannover, Germany
2000
Nominated for C3 position as Professor of Medicine at Muenster
University, Germany
2000
Associate Professor of Medicine at Tuebingen University
2004
Appointed Professor of Medicine, Director of Division of
Oncology / Hematology with sections Bone Marrow
Transplantation and Pneumology
2007
Nominated Director University Cancer Center Hamburg
Specialty Board Status:
1993
Certification – European Society for Medical Oncology
1995
Certification – German Board of Internal Medicine
1997
Certification – German Board of Internal Medicine:
Hematology-Medical Oncology
2000
Certification – Quality Management in Medicine
Professional Societies:
1991-present German Cancer Society (DKG)
1991-present Wilsede School of Oncology
1991-present European Society of Medical Oncology (ESMO)
1995-present American Society of Clinical Oncology (ASCO)
1995-present German Society of Hematology / Oncology (DGHO)
1998-present German Association for Bone Marrow and Blood Stem Cell
Transplantation (DAGKBT)
Honors /Awards:
Undergraduate
Member of the “Studienstiftung des deutschen Volkes”
(German Academic Scholarship Fund)
Award of the Ministry of Science for “Outstanding Student
Achievements in Medicine”
Graduate
2000 National Award of the German Cancer Society
2000 Award for Experimentel Urological Reseach
German Society of Urology
2001 Award of the Baden-Wuerttembergische Cancer
Society
2001 Award of the German Society for Clinical
Pharmacology
2002 Scientific Award for Medical Oncology (AIO)
2006 Award of the University of Heidelberg (Anita- und
Cuno-Wieland-Preis)
Committees:
1997-2004
Member of the Research Advisory Committee of the
University of Tuebingen
2000-2004
Founding member of the Interdisciplinary Center for GIcancer at Tuebingen University
2001-2004
Founding member of the Interdisciplinary Center for Soft
Tissue Sarcomas at Tuebingen University
2002-present
Chairman of the ESMO Examination Committee for
Medical Oncology
2002-present
Board member of the German Society for Haematology
and Oncology
2005-present
Board member of the German Cancer Society (DKG)
2005-present
Board member of the Cancer Society of Hamburg
Clinical Trials:
Experience in GCP-conform conduct of clinical studies as participant and
investigator for more than 15 years
Publications:
Editor of 10 books on oncology/supportive care
Author/coauthor 87 book chapters on Oncology/Hematology/Supportive Care
Author/coauthor of 329 original publications / reviews
10 most important publications
1.
Schwab M, Zanger UM, Marx C, Schaeffler E, Klein K, Dippon J, Kerb R,
Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M: Role of
genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a
prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol,
Mar 2008 - Epub ahead of print.
2.
Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher
J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German
Testicular Cancer Study Group: Phase I/II study of sequential dose-intensified
ifosfamide, cisplatin and etoposide plus paclitaxel as induction chemotherapy for
poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J
Clin Oncol 25: 5742-2747, 2007.
3.
Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY,
Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825),
a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type,
juxtamembrane, and activation loop mutant KIT isoforms associated with human
malignancies. Cancer Res 66: 473-481, 2006.
4.
Honecker F, Stoop H, de Krijger R, Lau C, Castrillon D, Oosterhuis J, Bokemeyer
C, Looijenga LHJ: Pathobiological implications of the expression of markers of
testicular carcinoma in situ by fetal germ cells. Am J Pathol 203:849-857, 2004.
5.
Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Rick O,
Hartmann JT, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C:
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with
intensively pretreated or refractory germ cell cancer: a study of the German
Testicular Cancer Study Group (GTCSG). J Clin Oncol 22:108-114, 2004.
6.
Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski
P, Schleicher J, Rick O, Beyer J, Hossfeld DK, Kanz L, Berdel WE, Andreesen R,
Bokemeyer C: Long-term results of first-line sequential high-dose VIPchemotherapy plus autologous stem cell support for patients with advanced
metastatic germ cell cancer: an extended phase I/II study of the german testicular
study group. J Clin Oncol 21:4083-4091, 2003.
7.
Bokemeyer C, Nichols C, Droz JP, Schmoll E, Horwich A, Gerl A, Fossa SD,
Beyer J, Pont J, Einhorn L, Hartmann JT: Extragonadal germ cell tumors of the
mediastinum and retroperitoneum - results from an international analysis. J Clin
Oncol 20:1864-1873, 2002.
8.
Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LHJ:
Microsatellite instability of germ cell tumors is associated with resistance to
systemic treatment. Cancer Res 62:2758-2760, 2002.
9.
C. Bokemeyer, A. J. M. Gillis, K. Pompe, F. Mayer, B. Metzner, N. Schleucher, J.
schleicher, G. Pflugrad-Jauch, J. Oosterhuis, L. Kanz, and L. Looijenga. Clinical
impact of germ cell tumor cells in apheresis products of patients receiving highdose chemotherapy. J Clin Oncol 19 (12):3029-3036, 2001
10. J. T. Hartmann, S. D. Fossa, C. Nichols, J. P. Droz, A. Horwich, A. Gerl, J. Beyer,
J. Pont, K. Fizazi, H. Hecker, L. Kanz, L. Einhorn, and C. Bokemeyer. Incidence of
metachronous testicular cancer in patients with extragonadal germ cell tumors. J
Natl.Cancer Inst. 93 (22):1733-1738, 2001.
11. J. T. Hartmann, C. R. Nichols, J. P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J.
Beyer, J. Pont, K. Fizazi, L. Einhorn, L. Kanz, and C. Bokemeyer. Hematologic
disorders associated with primary mediastinal nonseminomatous germ cell tumors.
J Natl.Cancer Inst. 92 (1):54-61, 2000.
12. C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer, B.
Metzner, J. T. Hartmann, H. J. Schmoll, L. Einhorn, L. Kanz, and C. Nichols. Firstline high-dose chemotherapy compared with standard-dose PEB/VIP
chemotherapy in patients with advanced germ cell tumors: A multivariate and
matched-pair analysis. J Clin Oncol 17 (11):3450-3456, 1999.
13. C. Bokemeyer, P. Nowak, A. Haupt, B. Metzner, H. Kohne, J. T. Hartmann, L.
Kanz, and H. J. Schmoll. Treatment of brain metastases in patients with testicular
cancer. J Clin Oncol 15 (4):1449-1454, 1997.
14. C. Bokemeyer, C. C. Berger, M. A. Kuczyk, and H. J. Schmoll. Evaluation of longterm toxicity after chemotherapy for testicular cancer. J Clin Oncol 14 (11):2923-
2932, 1996..